Prevalence of Liver Fibrosis and Progression of Liver Fibrosis
- Conditions
- HIV Infection and Chronic Alanine Aminotransferase Elevation
- Interventions
- Other: Fibroscan
- Registration Number
- NCT01208376
- Lead Sponsor
- Helen Kovari-Kramer
- Brief Summary
Little is known about the clinical significance of chronic alanine aminotransferase (ALT) elevation in HIV-infected patients without hepatitis B and C coinfection. Study aim is first to evaluate the prevalence of liver fibrosis and cirrhosis in HIV-infected patients with chronic ALT elevation and no chronic viral hepatitis using non-invasive diagnostic tests and second to find associated factors with significant fibrosis and cirrhosis. In a second longitudinal part we intend to assess fibrosis progression within 1 and 3 years.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 195
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description always normal ALT Fibroscan Control patients: HIV-infected, always normal ALT values unexplained chronic ALT elevation Fibroscan Case patients: HIV-infected, unexplained chronic alanine aminotransferase (ALT) elevation
- Primary Outcome Measures
Name Time Method Liverfibrosis 3 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University Hospital Zurich
🇨ðŸ‡Zurich, Switzerland